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Abstract
 
gp49B1 is an immunoglobulin (Ig) superfamily member that inhibits Fc
 
 
 
RI-induced mast cell
activation when the two receptors are coligated with antibodies in vitro. The critical question
of in vivo function of gp49B1 is now addressed in gene-disrupted mice. gp49B1-deficient mice
exhibited a significantly increased sensitivity to IgE-dependent passive cutaneous anaphylaxis as
assessed by greater tissue swelling and mast cell degranulation in situ. Importantly, by the same
criteria, the absence of gp49B1 also resulted in a lower threshold for antigen challenge in active
cutaneous anaphylaxis, in which the antigen-specific antibody levels were comparable in
gp49B1-deficient and sufficient mice. Moreover, the absence of gp49B1 resulted in a signifi-
cantly greater and faster death rate in active systemic anaphylaxis. These results indicate that
gp49B1 innately dampens adaptive immediate hypersensitivity responses by suppressing mast
cell activation in vivo. In addition, this study provides a new concept and target for regulation
of allergic disease susceptibility and severity.
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Introduction
 
Gp49B1 is a member of the Ig superfamily with two extra-
cellular C2-type domains (1, 2) and two cytosolic immu-
noreceptor tyrosine-based inhibitory motifs (ITIMs) (3).
This transmembrane receptor is expressed on mast cells (4),
macrophages (5, 6), and cytokine- or virally stimulated NK
cells (7–9). Gp49B1 is encoded by the 
 
gp49B
 
 gene (2),
whereas the highly homologous 
 
gp49A
 
 gene (10) encodes
the gp49A protein that does not have an ITIM (1) and, like
gp49B1, is expressed in higher amounts on immature bone
marrow–derived mast cell (BMMC) progenitors than on
mature peritoneal mast cells (4, 10). Ab-mediated co-
ligation of gp49B1 to Fc
 
 
 
RI inhibits IgE-induced mast
cell activation in vitro (3) by a mechanism requiring the
ITIM tyrosines of gp49B1 and the src homology domain
2–containing phosphatase (SHP)-1 (11).
The ITIM was first identified in Fc
 
 
 
RIIB (12, 13),
whose extracellular domain is only distantly related to
gp49B1 (3). Fc
 
 
 
RIIB also differs because its ITIM inhibits
cell activation through the recruitment of a src homology
domain 2–containing inositol polyphosphate 5-phosphatase
(SHIP) (14). Fc
 
 
 
RIIB is widely expressed in the immune
system, including on B cells and mast cells, and inhibits cell
activation signaled by the B cell receptor and Fc
 
 
 
RI in
vitro (12, 13). Fc
 
 
 
RIIB-deficient mice exhibit increased
vascular permeability in IgG-dependent passive cutaneous
anaphylaxis (PCA) (15) and a higher death rate during IgG-
or IgE-dependent passive systemic anaphylaxis compared
with normal mice (16). Because both IgE- and IgG-antigen
complexes bind Fc
 
 
 
RIIB (17), the increase in sensitivity of
the deficient mice to anaphylactic reactions reflects the loss
of direct feedback counterregulation during adaptive im-
mediate hypersensitivity reactions.
The gp49 family is homologous with other families of
activating and inhibitory receptors of the Ig superfamily
that have C-2 type domains and are expressed on various
cell types in the immune system. The inhibitory members
of the human killer cell Ig-like receptor (KIR), leukocyte
Ig-like receptor (LIR), and mouse paired Ig-like receptor
(PIR) families share with gp49B1 the expression of ITIMs
that recruit SHP-1 (for reviews, see references 18–20). The
ligands for KIRs and two of the LIRs are polymorphic
MHC class I molecules, and the binding of autologous class
I by the receptors provides self-recognition that counter-
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regulates inappropriate activation signals. The ligands for
the PIRs and most of the LIRs are unknown.
We recently identified the integrin 
 
 
 
v
 
 
 
3 as a functional
ligand for gp49B1 in vitro (21). 
 
 
 
v
 
 
 
3 is widely distributed
in vivo, being expressed on endothelial cells, fibroblasts, ep-
ithelial cells, and certain hematopoietic lineage cells (for a
review, see reference 22). However, before addressing the
ligand in vivo, it was critical to determine whether the ab-
sence of gp49B1 provided a mast cell phenotype with in-
creased sensitivity to Fc
 
 
 
RI-mediated, antigen-specific ac-
tivation. We therefore generated mice with a targeted
disruption of the 
 
gp49B
 
 gene and focused on the effects of
gp49B1 deficiency on local and systemic anaphylactic re-
actions that have a major mast cell component. In PCA
with defined IgE inputs, 
 
gp49B
 
 
 
/
 
 
 
 mice showed markedly
greater and prolonged tissue swelling concomitant with a
more extensive degranulation of tissue mast cells compared
with 
 
gp49B
 
 
 
/
 
 
 
 mice. The increase in tissue swelling and the
accelerated and greater rate of anaphylactic death in active
cutaneous and systemic anaphylaxis, respectively, in gp49B-
deficient mice, establishes for the first time the capacity of
an ITIM-bearing receptor to attenuate active immediate
hypersensitivity reactions. Thus, our results recognize a hy-
perresponsive mast cell phenotype in 
 
gp49B
 
 
 
/
 
 
 
 mice,
which in normal mice is dynamically counterregulated by
the interaction of gp49B1 with innate tissue elements.
 
Materials and Methods
 
Generation of gp49B
 
 
 
/
 
 
 
 Mice.
 
A 6.4-kb 129/Sv EcoRI
 
→
 
HindIII genomic fragment containing the 
 
gp49B
 
 gene was sub-
cloned into a modified pBluescript vector that had a thymidine ki-
nase gene on the 3
 
 
 
 end. The region between the NcoI sites in in-
tron 2 and exon 3 of the gp49B gene (2) was excised and replaced
with the pMC1neo vector in the forward orientation (see Fig. 1
A). The targeting construct was transfected by electroporation
into 129/Sv embryonic stem (ES) cells, and cells were selected
with G418 and gancyclovir. To confirm homologous recombina-
tion, genomic DNA was extracted from the drug-selected cells,
digested with SphI, and hybridized with a HindIII
 
→
 
SphI probe
common to the 3
 
 
 
 regions of the 
 
gp49A
 
 and 
 
gp49B
 
 genes (see Fig.
1 A). The probe was predicted to hybridize with a 4.8-kb band
reflecting the disrupted gp49B gene and with an 
 
 
 
9.5-kb band
from the wild-type gp49B gene. All the clones had a 3.6-kb frag-
ment from the wild-type gp49A gene, which has an SphI site in
intron 5 that is not present in the gp49B gene (10). When the
same blots were hybridized with an XhoI
 
→
 
SalI pMC1Neo
probe, the clones that showed disruption of the gp49B gene with
the HindIII
 
→
 
SphI probe demonstrated 
 
 
 
5.8- and 4.8-kb bands
consistent with the gene disruption (data not shown). Moreover,
there were no bands indicative of unintentional disruption of the
gp49A gene. One of the clones with a disrupted 
 
gp49B
 
 gene (no.
69) was injected into BALB/c blastocysts, and chimeric mice were
generated and crossed with BALB/c mice to produce male and fe-
male 
 
gp49B
 
 
 
/
 
 
 
 mice. Those mice were intercrossed to yield
 
gp49B
 
 
 
/
 
 
 
, 
 
gp49B
 
 
 
/
 
 
 
, and 
 
gp49B
 
 
 
/
 
 
 
 mice (see Fig. 1 B). The ho-
mozygous mice on the 129/Sv 
 
 
 
 BALB/c background were then
bred to yield
 
 gp49B
 
 
 
/
 
 
 
 and
 
 gp49B
 
 
 
/
 
 
 
 mice for study. All animal
studies were approved by the Animal Care and Use Committee of
the Dana-Farber Cancer Institute.
 
Culture of BMMC.
 
Bone marrow cells from 
 
gp49B
 
 
 
/
 
 
 
 and
 
gp49B
 
 
 
/
 
 
 
 mice were cultured for 3–8 wk in enriched medium
containing 50% WEHI-3 cell (American Type Culture Collec-
tion) conditioned medium as described (3). After 3 wk, 
 
 
 
97% of
the nonadherent cells in the cultures were mast cells as assessed by
metachromatic staining with toluidine blue.
 
Flow Cytometry.
 
Cells (2.5 
 
 
 
 10
 
5
 
) were incubated in 25 
 
 
 
l of
calcium- and magnesium-free HBSS supplemented with 0.1%
BSA and 0.02% sodium azide (HBA) alone or with saturating
amounts of either rat mAb B23.1 (3) or rabbit anti-gp49
 
201–216
 
(10) for 30 min at 4
 
 
 
C. Cells were washed with HBA, incubated
for 30 min at 4
 
 
 
C with FITC-labeled, F(ab
 
 
 
)
 
2
 
 fragments of either
goat IgG anti–rat IgM or goat anti–rabbit IgG-Fc (Jackson Im-
munoResearch Laboratories) as appropriate for the first Ab,
and washed again with HBA. Cells were resuspended in 2% para-
formaldehyde in HBSS and analyzed on a Becton Dickinson
FACSort™ using logarithmic fluorescence amplification.
 
PCA.
 
The left and right ears of mice were injected intrader-
mally with 20 
 
 
 
l of saline alone or containing 25 or 2.5 ng of
mouse monoclonal IgE anti-DNP (clone SPE-7; Sigma-Aldrich),
respectively. 20 h later, the mice were challenged with a 100 
 
 
 
l
intravenous injection containing 100 
 
 
 
g of DNP-human serum
albumin (HSA; Sigma-Aldrich), and ear thickness measurements
were made with a caliper (Dyer Company). Net ear swelling was
calculated as the difference between the thicknesses of the right
and left ears of each mouse.
 
Active Cutaneous and Systemic Anaphylaxis.
 
Mice were immu-
nized intraperitoneally on days 0 and 5 with 10 
 
 
 
g of chicken
OVA adsorbed to 1 mg of alum. Approximately 3 wk after the
initial injection, the left and right ears of mice were injected in-
tradermally with 20 
 
 
 
l of saline alone or containing 50 ng OVA,
respectively. Net ear swelling was calculated as for PCA. For sys-
temic anaphylaxis, immunized mice were injected intravenously
with 10 mg of OVA in 100 
 
 
 
l of PBS. The outcome was quanti-
fied by the number of animals dying and the time to death.
 
Histology.
 
Ears were excised, fixed in 4% paraformaldehyde
for at least 8 h, and embedded in glycolmethacrylate. Sections (2
 
 
 
m) were placed on slides, air dried, and stained for 20 s in a 5%
ethanolic solution of toluidine blue or in Diff-Quik (Dade Beh-
ring, Inc.). For enumeration of intact mast cells, 10 high power
fields (50
 
 
 
 objective) of each ear were examined on a Leica Di-
alux 20 microscope.
 
Statistical Analyses.
 
Significance was assessed with Student’s
unpaired, two-tailed 
 
t
 
 test.
 
 P 
 
values 
 
 
 
 0.05 were considered to be
significant.
 
Results and Discussion
 
Generation of gp49B
 
 
 
/
 
 
 
 Mice.
 
ES cells (129/Sv strain)
were transfected with a targeting construct that had a
pMc1Neo construct replacing a region of the 
 
gp49B
 
 gene
running from intron 2 through most of exon 3 (that en-
codes the NH
 
2
 
-terminal Ig-like domain; Fig. 1 A). Of 104
G418- and gancyclovir-resistant clones, 2 had a disrupted
 
gp49B
 
 gene by Southern blot analyses. A clone was micro-
injected into blastocysts from BALB/c mice to generate
chimeric mice, which were bred to BALB/c mice to
produce heterozygotes that were then intercrossed to
yield 
 
gp49B
 
 
 
/
 
 
 
, 
 
gp49B
 
 
 
/
 
 
 
, and 
 
gp49B
 
 
 
/
 
 
 
 mice (Fig. 1 B).
 
gp49B
 
 
 
/
 
 
 
 mice were fertile, had litters of normal size, and
remained healthy when living in a viral Ab-free, barrier vi- 
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varium. Similarly, naive 
 
gp49B
 
 
 
/
 
 
 
 mice in a mixed 129 
 
 
 
C57BL/6 background were reported to be normal for
these characteristics (23).
The expression of gp49B1 and gp49A proteins was as-
sessed on BMMCs from 
 
gp49B
 
 
 
/
 
 
 
 and
 
 gp49B
 
 
 
/
 
 
 
 mice.
The gp49B1-specific mAb B23.1 (3) bound to BMMCs
generated from 
 
gp49B
 
 / , but not gp49B /  mice (Fig. 1
C). gp49A-specific anti-gp49201–216 (10) bound equivalently
to BMMCs from gp49B /  and gp49B /  mice. In addi-
tion, peritoneal mast cells from gp49B /  mice did not
bind mAb B23.1, as assessed by two-color flow cytometry
using anti–c-kit to identify mast cells (data not shown).
Hence, the gp49B gene product was specifically absent in
cells from gp49B /  mice. These results also confirm our
previous conclusion, based on flow cytometric analyses
of gp49A and gp49B transfectants, that mAb B23.1 is
gp49B1-specific (3).
Effects of gp49B1 Deficiency on PCA. To determine
whether gp49B1 regulates Fc RI-mediated mast cell acti-
vation in vivo, we tested the effects of gp49B1 deficiency
on the IgE-mediated PCA reaction in the ear. Passive sen-
sitization with a defined input of IgE assures that subse-
quent antigen challenge is directed to the mast cells (24)
and avoids the variation in titers of Ab classes that can oc-
cur with active sensitization. The left and right ears of mice
were injected intradermally with saline or monoclonal IgE
anti-DNP, respectively. 20 h later, the mice were chal-
lenged with an intravenous injection of DNP-HSA (100
 g), and initial measurements were made 0.5 h later, a time
that falls within the 15 to 45 min plateau of the peak re-
sponse (25). The net swelling in the ears of gp49B /  mice
declined progressively from the 0.5 h time point and was
essentially undetectable by 4 h (Fig. 2 A). The sensitized
ears of gp49B /  mice showed two- to threefold greater
net swelling at 0.5 to 2 h after challenge compared with
gp49B /  mice, and also declined progressively from the
0.5 h peak response with barely detectable swelling at 4 and
8 h. Enhanced swelling in the ears of the deficient mice
was also evident histologically 0.5 h after challenge and was
due to separation of the structural elements by edema,
which had largely subsided in both genotypes by 4 h (Fig. 2
B). There was no influx of neutrophils, eosinophils, or
other cell types evident within the time frame for the net
tissue swelling. Importantly, the number of morphologi-
cally intact mast cells, defined as cells with metachromatic
granules associated with a nucleus, was a significant twofold
lower at both 0.5 and 4 h after challenge of gp49B /  mice
(Fig. 2 C), indicative of an enhanced susceptibility to mast
cell degranulation in the deficient animals.
To determine whether this augmented mast cell response
reflected a reduced requirement for the concentration of
sensitizing IgE, the PCA reaction was conducted with an
Figure 1. Generation of gp49B /  mice. (A)
Genomic organization of the mouse gp49A and
gp49B genes (top), structure of the targeting vector
(middle), and organization of the disrupted allele.
The expected fragment sizes of 3.6,  9.5, and 4.8
kb for the wild-type (WT) gp49A, WT gp49B,
and disrupted gp49B genes, respectively, in the
blot analysis in B are indicated by brackets. E,
EcoRI; N, NcoI; Sp, SphI; H, HindIII;  3, trun-
cated exon 3. (B) DNA blot analysis of SphI-
digested genomic DNA identifying gp49B / ,
gp49B / , and gp49B /  mice by hybridization
with a HindIII→SphI gp49A/gp49B1 genomic
fragment to provide the fragment sizes defined in
panel A. (C) Flow cytometric analysis of BMMCs
from gp49B /  and gp49B /  mice stained with
mAb B23.1 (anti-gp49B1; top panels, thick lines)
or polyclonal anti-gp49201–216 (anti-gp49A; bottom
panels, thick lines) and the respective negative con-
trols (thin lines).230 Augmented Mast Cell Activation in gp49B1-deficient Mice
intradermal injection of 2.5 ng of IgE, a dose that is 10- to
100-fold lower than is customarily used (24, 26). In
gp49B /  mice, maximal swelling at 0.5 h was one-half that
obtained with 25 ng of IgE and was undetectable beyond
1 h (Fig. 2 D). The ear swelling in gp49B /  mice was also
lower than that observed with the higher IgE dose, but was
dramatically greater than that of gp49B /  mice at the low
IgE dose (Fig. 2 D). Furthermore, the magnitude of the ear
swelling in gp49B /  mice with low dose IgE sensitization
was equivalent to that of gp49B /  mice sensitized with 10-
fold more IgE. Thus, the gp49B /  mouse has an elicited
phenotype of enhanced susceptibility to IgE-mediated mast
cell activation over a 10-fold range of IgE sensitizing con-
centrations in situ. Inasmuch as the rapid and edematous tis-
sue swelling in PCA is mast cell dependent (24), our find-
ings establish conclusively that gp49B1 is an endogenous
inhibitor of IgE-mediated mast cell activation in vivo. The
observation of others that IgE-initiated degranulation of
BMMC from gp49B /  and gp49B /  mice is comparable
in vitro (23) could be explained by the absence of a tissue
ligand for gp49B1 in those cell suspensions.
Recently, mice deficient in leukotriene (LT)C4 synthase
were found to exhibit attenuated ear swelling in IgE-
dependent PCA (25), revealing a previously unappreciated
contribution of mast cell–derived LTC4 and its receptor-
active metabolites in immediate tissue swelling. PCA with
50 ng IgE was attenuated in LTC4 synthase-deficient mice
by 50% compared with normal littermates (25), indicating
that the cysteinyl leukotrienes are as significant as the amine
mediators exocytosed from mast cell secretory granules in
terms of the induction of early edema. Because coligation
of gp49B1 with cross-linked Fc RI inhibits the generation
of LTC4 by mast cells in vitro (3), it seems likely that the
augmented production of cysteinyl leukotrienes and/or
their synergistic action with the released amines contributes
to the increase in PCA-associated tissue swelling in
gp49B /  mice.
Effects of gp49B1-deficiency on Acute Active Cutaneous Ana-
phylaxis. To more fully assess the biologic relevance of
gp49B1 in the negative regulation of immediate hypersen-
sitivity, we used a model of active cutaneous anaphylaxis.
OVA-immunized gp49B /  mice that were challenged in-
tradermally in the ear with 50 ng of antigen demonstrated
little tissue swelling as measured by micrometry (Fig. 3 A)
or histology (Fig. 3 B), despite an antigen-specific Ab re-
sponse (Table I). In striking contrast, gp49B /  mice with a
Figure 2. Effects of gp49B1
deficiency on PCA assessed by
ear swelling and histology. Mice
were injected intradermally with
20  l of saline alone (left ears) or
containing 25 (A–C) or 2.5 (D)
ng of mouse monoclonal IgE
anti-DNP (right ears). After
20 h, the mice were injected in-
travenously with 100  g of
DNP-HSA in 100  l of PBS. (A
and D) Time course of net ear
swelling (right ear minus left ear)
measured with a thickness cali-
per. Data are expressed as
mean   SD, n   4. (B) Diff-
Quik–stained tissue sections of
control and challenged ears
(control ears obtained from mice
not injected with IgE); original
magnification: 10 . (C) Quan-
tification of intact mast cells, de-
fined as having metachromatic
cytoplasmic granules surround-
ing an intact nucleus, per high
power field (HPF) in tissue sec-
tions from the ears of gp49B / 
(black bars) and gp49B / 
(hatched bars) mice 0.5 and 4 h,
respectively, after antigen chal-
lenge. Data are expressed as
mean   SD, n   3. *P   0.05
compared with gp49B /  mice.231 Daheshia et al. Brief Definitive Report
comparable Ab response showed robust swelling at 0.5 h
that was somewhat greater than that obtained by PCA with
25 ng of hapten-specific IgE (Fig. 2 A), and which con-
sisted of edema without a cellular infiltrate (Fig. 3 B). The
challenged ears of gp49B /  mice showed fourfold fewer
intact mast cells 0.5 h after challenge compared with
gp49B /  mice as noted histologically (Fig. 3 C) and quan-
tified by cell counting (Fig. 3 D).
Whereas the contribution of mast cells to early tissue
swelling in active anaphylaxis in mice has not been formally
established, the decrease in intact mast cells 0.5 h after in-
tradermal antigen challenge of immunized gp49B1-defi-
cient mice (Fig. 3 C) suggests that a concomitant, aug-
mented release of vasoactive mediators from mast cells
accounts for the tissue edema (Fig. 3 B). Moreover, the
findings indicate that the absence of gp49B1 augments the
effector phase of a polyclonal, acquired immune response
that likely involves mast cell activation through both IgE/
Fc RI and IgG/Fc RIII.
Effect of gp49B1 Deficiency on Active Systemic Anaphy-
laxis. Mice immunized with OVA were injected intrave-
nously with 10 mg OVA. Initial observations suggested
that  gp49B /  mice became moribund more frequently
and rapidly than normal animals, so the outcome was quan-
tified in additional experiments. Whereas 8 out of 29 (27%)
gp49B /  mice died in response to systemic antigen chal-
lenge, 17 out of 25 (68%) gp49B /  mice died. Moreover,
the mean times to death were 45   9 and 26   8 min in
gp49B /  and gp49B /  mice, respectively, which were
significantly different (P   0.0001). In two out of three
gp49B /  mice that died, the lungs showed focal leukose-
Figure 3. Effects of gp49B1
deficiency on active cutaneous
anaphylaxis. Mice were injected
on day 0 and 5 with 10  g of
OVA adsorbed to 1 mg of alum.
Three wk after the initial injec-
tion, the left and right ears of
mice were injected intradermally
with 20  l of saline alone or
containing 50 ng OVA, respec-
tively. (A) Time course of net
ear swelling measured as de-
scribed in the legend to Fig. 2.
Data are expressed as mean  
SD,  n    3. (B) Diff-Quik–
stained tissue sections of control
and challenged ears 0.5 h after
intradermal injection; original
magnification: 10 . (C) Higher
magnification (100  objective)
of tissue sections represented in
B showing intact and degranu-
lated mast cells. (D) Quantifica-
tion of intact mast cells in tissue
sections from ears 0.5 h after in-
jection with PBS (white bars) or
OVA (hatched bars), measured as
described in the legend to Fig. 2.
Data are expressed as mean  
SD, n   3. *P   0.05 compared
with gp49B /  mice.
Table I. OVA-specific Serum Ig Levels at Day 20 in Immunized 
gp49B /  and gp49B /  Mice
gp49B /  gp49B / 
IgG 122   71 134   112
IgG1 251   199 222   189
IgG2a 924   1,470 954   893
IgM 0.172   0.105 0.199   0.036
IgE 151   149 101   66
Data are expressed as mean ng/ml   SD (n   8).232 Augmented Mast Cell Activation in gp49B1-deficient Mice
questration of neutrophils and mast cells had degranulated
in the trachea. In the heart, myocyte swelling with dis-
torted myofibrils was associated with mast cell degranula-
tion. Mast cell degranulation was not seen in three gp49B / 
mice at the interval by which the gp49B /  mice died.
That the mast cell can be responsible for a fatal outcome
has been established in passive models using anti-IgE or IgE
sensitization followed by antigen, in which death occurs
within 40 to 60 min in WBB6F1- /  mice, but mast
cell–deficient WBB6F1-W/Wv mice survive (27–29). In
active systemic anaphylaxis with these two strains of mice,
the mast cell contribution was most evident for the cardiac
tachycardia, and death was not dependent on the mast cell,
thus reflecting other pathways (27, 28). Hence, while the
mast cell may not be the absolute cause of death in gp49B / 
mice, the susceptibility of the gp49B /  mice to fatal active
systemic anaphylaxis in a relatively short interval compared
with  gp49B /  mice is compatible with an augmented
burst of mediator release from mast cells.
In summary, our results establish that gp49B1 is an inhib-
itor of Fc RI-directed mast cell activation and attendant
immediate hypersensitivity reactions in vivo. This constitu-
tive effect of gp49B1 is sufficiently robust to attenuate the
local and systemic anaphylactic effects of antigen challenge
during an ongoing immune response. Thus, tissue mast cells
through their expression of gp49B1 possess an innate system
that counterregulates acquired allergic inflammation.
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